Conferences
ASCO GU 2024: Subgroup Analyses of Efficacy Outcomes by Baseline Tumor Size in the Phase 3, Open-label CLEAR Trial
January 28, 2024
ASCO GU 2024: Phase 1b/2 Study of Combination 177Lu Girentuximab plus Cabozantinib and Nivolumab in Treatment Naive Patients with Advanced Clear Cell RCC
January 28, 2024
ASCO GU 2024: Development of a Patient-Centered HRQOL Measure for Metastatic RCC: A Three-Phase Study
January 28, 2024
ASCO GU 2024: Utility of Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Disease Monitoring in Patients with Non-Seminomatous Germ-Cell Tumor
January 27, 2024
ASCO GU 2024: Longitudinal Tumor-Informed ctDNA Assay and Patient Outcomes in Testicular Cancer
January 27, 2024
ASCO GU 2024: Nivolumab plus Cabozantinib vs Sunitinib for Previously Untreated Advanced RCC: Results from 55-Month Follow-up of the CheckMate 9ER Trial
January 27, 2024
ASCO GU 2024: Survivorship Issues Beyond 2 Years After Treatment in Testicular Germ Cell Tumors: Experience from a Large Center in the United Kingdom
January 27, 2024
ASCO GU 2024: First-line Pembrolizumab plus Lenvatinib for Non–clear Cell RCC: Extended Follow-up of the Phase 2 KEYNOTE-B61 Study
January 27, 2024